Trial Profile
Stereotactic Body Radiotherapy Radiotherapy With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms STILE
- 20 Feb 2024 Planned End Date changed from 1 Jan 2022 to 1 Feb 2026.
- 20 Feb 2024 Planned primary completion date changed from 1 Jun 2021 to 1 Aug 2024.
- 20 Feb 2024 Status changed from recruiting to active, no longer recruiting.